Patents by Inventor Richard A. Silva

Richard A. Silva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20190240252
    Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m, and used for treating patients, for example, patients with hyperphosphatemia.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 8, 2019
    Inventors: Stephen Randall HOLMES-FARLEY, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 10370389
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 6, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20190112320
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: September 12, 2018
    Publication date: April 18, 2019
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20190010169
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: January 3, 2018
    Publication date: January 10, 2019
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES
    Publication number: 20180339989
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine monomer compounds and their synthetic precursors.
    Type: Application
    Filed: April 19, 2018
    Publication date: November 29, 2018
    Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 10081640
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: September 25, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20180251474
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: January 24, 2018
    Publication date: September 6, 2018
    Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20180201626
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 19, 2018
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
    Publication number: 20180093981
    Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: April 5, 2018
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 9890179
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 13, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 9873708
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 23, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
    Patent number: 9744153
    Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 29, 2017
    Assignee: Genzyme Corporation
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
  • 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
    Patent number: 9745294
    Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 29, 2017
    Assignee: Genzyme Corporation
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20170051011
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: July 21, 2016
    Publication date: February 23, 2017
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20170050985
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: July 21, 2016
    Publication date: February 23, 2017
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
    Publication number: 20170050986
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Application
    Filed: July 21, 2016
    Publication date: February 23, 2017
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
    Publication number: 20160338996
    Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 21, 2016
    Publication date: November 24, 2016
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20160158275
    Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m, and used for treating patients, for example, patients with hyperphosphatemia.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 9, 2016
    Inventors: Stephen Randall HOLMES-FARLEY, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
  • 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
    Patent number: 9272996
    Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: March 1, 2016
    Assignee: Genzyme Corporation
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
  • 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
    Publication number: 20150225393
    Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 16, 2014
    Publication date: August 13, 2015
    Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao